Published in:
01-07-2019 | Cerebral Metastase | Image of the Month
Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617
Authors:
Mike M. Sathekge, Frank Bruchertseifer, Ismaheel O. Lawal, Mariza Vorster, Otto Knoesen, Thabo Lengana, Tebatso G. Boshomane, Kgomotso K. Mokoala, Alfred Morgenstern
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Issue 8/2019
Login to get access
Excerpt
Brain metastases are not common in prostate cancer; they typically occur in patients with end-stage disease who are castrate-resistant. Patients with brain metastases have very limited survival [
1]. Traditionally, the mainstays of therapy have been surgical resection, chemotherapy and external beam radiotherapy. Recently, combination of
177Lu-Prostate-specific membrane antigen (PSMA)-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer (mCRPC) showed significant regression in the sizes and PSMA-ligand avidity of the lesions over time [
2]. Recent studies have demonstrated that targeted α-radiation therapy with
225Ac-PSMA-ligand can significantly benefit patients with mCRPC in the appropriate setting [
3,
4]. Targeted α-radiation therapy may be more effective for the treatment of mCRPC, and has been shown, in a limited number of patients, to be effective in the setting of resistant to
177Lu-PSMA-617 therapy [
5]. …
